Loading organizations...
Venvest Capital operates as an opportunistic equity investment and buyout firm, primarily focused on providing liquidity through secondary market opportunities. The firm specializes in acquiring stakes from founders, early employees, and seed investors, offering strategic capital and operational expertise to propel growth. They target product or service-oriented businesses, often with a distribution component, that stand to benefit from enhanced operational efficiencies or innovative marketing channel strategies.
Rani Aliahmad founded Venvest Capital in 2014, establishing the firm out of Santa Monica, California. Aliahmad, an experienced entrepreneur and investor with a significant background in both venture capital and private equity industries, identified a market need for a dedicated secondary market opportunity fund. His previous tenure as CEO of Trend Media underscored his understanding of business development and investment, shaping the firm's focus on strategic value creation.
The firm's clients include founders, early employees, and seed investors seeking exit opportunities, as well as businesses requiring equity investment and strategic guidance for expansion. Venvest Capital’s vision centers on identifying and investing in companies that possess strong growth potential, leveraging its hands-on approach to enhance market position and drive long-term value for its portfolio and partners.
Venvest Capital has 3 tracked investments across 1 company. The latest tracked deal is $40.0M Series B in Sienna Biopharmaceuticals in April 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 24, 2017 | Sienna Biopharmaceuticals | $40.0M Series B | ARCH Venture Partners, Venvest Capital | David Pyott, Altitude Life Science Ventures, Fidelity Management & Research Company, Omega Funds, Partner Fund Management |
| Jul 12, 2016 | Sienna Biopharmaceuticals | $12.0M Series A Extension | ARCH Venture Partners, Partner Fund Management | Altitude Life Science Ventures, TWO River |
| Apr 28, 2016 | Sienna Biopharmaceuticals | $34.0M Series A | Kristina Burow | Altitude Life Science Ventures, Partner Fund Management |